Zusammenfassung
Die akute Lungenembolie ist die dritthäufigste akute kardiovaskuläre Erkrankung und
geht mit einer durchschnittlichen Letalitätsrate von bis zu 10% innerhalb der ersten
3 Monate einher. Themen dieses Übersichtsartikels sind insbesondere die risikoadaptierte
Diagnostik und Therapie der akuten Lungenembolie.
Abstract
Acute pulmonary embolism (PE) is the third most frequent acute cardiovascular disease
with an overall annual incidence of 100 – 200 cases per 100.000 population and a high
mortality rate of up to 10% over the first 3 months after diagnosis. This article
summarises and critically discusses the recommendations of current guidelines and
the most relevant recent data on risk stratification, reperfusion, and anticoagulation
treatment of acute PE. We particularly focus on (i) the evolving definition of intermediate-risk
PE and its implications for initial treatment; (ii) advances in pharmacological and
catheter-directed thrombus lysis; and (iii) the benefits versus risks of extended,
indefinite anticoagulation after PE based on the available tools for assessment of
the patientʼs recurrence versus bleeding risk.
Schlüsselwörter
Lungenembolie - Risikostratifizierung - Thrombolyse - Antikoagulation - Rezidiv -
Blutung
Key words
pulmonary embolism - risk stratification thrombolysis - anticoagulation - PE recurrence
- bleeding
